Mycophenolic acid concentrations in long-term heart transplant patients: Relationship with calcineurin antagonists and acute rejection

Clinical Transplantation

Volumn 16, Issue 3, 2002, Pages 196-201

  Cantin, Bernard ^a   Giannetti, Nadia ^b   Parekh, Hemal ^c   Panchal, Shyam N ^a   Kwok, Bernard W K ^a   Najem, Ruhina ^a   Woodman, Katina ^a   Hunt, Sharon A ^a   Valantine, Hannah A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c KAISER PERMANENTE   (United States)

Author keywords

Calcineurin antagonists; Heart transplantation; Mycophenolic acid; Rejection

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKOPENIA; MALE; MEDICAL DOCUMENTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL MORTALITY; SURGICAL PATIENT; SURVIVAL TIME; SYMPTOMATOLOGY;

AGED; CALCINEURIN; CYCLOSPORINE; ENZYME INHIBITORS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMP DEHYDROGENASE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS;

EID: 0036303980     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2002.01122.x     Document Type: Article

References (24)

1. The use of mycophenolate mofetil in transplant recipients
2. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients
3. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators
4. Mycophenolic acid concentrations are associated with cardiac allograft rejection
5. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring
6. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection
7. High-performance liquid chromatographic method for the determination of mycophenolate mofetil in human plasma
8. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group. The International Society for Heart Transplantation
9. Identification patients not requiring endomyocardial biopsies late after cardiac transplantation
10. Routine surveillance endomyocardial biopsy continues to detect significant rejection late after heart transplantation
11. Natural history of focal moderate cardiac allograft rejection. Is treatment warranted?
12. Natural course of moderate cardiac allograft rejection (International Society For Heart Transplantation grade 2) early and late after transplantation
13. Repetitive nontreated episodes of grade 1b or 2 acute rejection impair long-term cardiac graft function
14. Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease
15. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: Time for a reappraisal
16. Does acute rejection correlate with the development of transplant coronary artery disease? A multicenter study using intravascular ultrasound
17. Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens
18. Pharmacokinetics mycophenolate mofetil (RS61443): A short review
19. Clinical pharmacokinetics mycophenolate mofetil
20. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function
21. Mycophenolic acid plasma concentrations: Influence of comedication
22. Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy
23. Evidence that tacrolimus augments the bio-availability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation
24. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid